Please use this identifier to cite or link to this item:
Title: Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans.
Authors: Ribeiro, Patrícia Aparecida Fernandes
Dias, Daniel Silva
Lage, Daniela Pagliara
Costa, Lourena Emanuele
Martins, Vivian Tamietti
Tavares, Grasiele de Sousa Vieira
Mendonça, Débora Vasconcelos Costa
Lima, Mariana Pedrosa
Oliveira, Jamil Silvano de
Steiner, Bethina Trevisol
Ávila, Ricardo Andrez Machado de
Roatt, Bruno Mendes
Chávez Fumagalli, Miguel Angel
Souza, Daniel Menezes
Duarte, Mariana Costa
Teixeira Junior, Antonio Lucio
Coelho, Eduardo Antônio Ferraz
Keywords: Leishmaniasis
Delivery systems
DNA plasmid
Recombinant protein
Issue Date: 2018
Citation: RIBEIRO, P. A. F. et al. Evaluation of a Leishmania hypothetical protein administered as DNA vaccine or recombinant protein against Leishmania infantum infection and its immunogenicity in humans. Cellular Immunology, v. 331, p. 67-77, set. 2018. Disponível em: <>. Acesso em: 22 fev. 2019.
Abstract: Visceral leishmaniasis (VL) is a fatal disease when acute and untreated. The treatment against this disease is long and presents toxicity and/or high costs. Moreover, parasite resistance has been increasing. Therefore, alternative control measures to avoid the spread of disease should be considered. It is accepted that the development of the T helper (Th)1 immune response, based on the production of pro-inflammatory cytokines, is required for the control of parasites. Although recombinant protein-based vaccines have been tested against VL, they require supplementation with immune adjuvants. In addition, there is a scarcity of studies that comparatively evaluate the efficacy of the immunogens when administered by different delivery systems in mammalian hosts. In the present study, a Leishmania hypothetical protein, LiHyR, was cloned and evaluated by immunization as a plasmid deoxyribonucleic acid (DNA) vaccine or in a recombinant format plus saponin against Leishmania infantum infection. Results showed that both vaccination regimens induced a Th1 cell-based immunity, since high levels of interferon-gamma (IFN-γ), interleukin (IL)-2, IL-12, granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor alpha (TNF-α) were found, and were associated with the low production of IL-4, IL-10, and anti-parasite immunoglobulin (IgG)1 isotype. In addition, significant reductions in the parasite load were found in the evaluated organs of the DNA LiHyR or rLiHyR/saponin-vaccinated animals. No significant difference was achieved between groups vaccinated with DNA or the recombinant protein. The antigen proved to be also immunogenic in human peripheral blood mononuclear cells (PBMCs) collected from healthy subjects and from untreated and treated VL patients. A higher IgG2 isotype was also found in sera samples of these subjects, thus demonstrating its possible use as a human vaccine. This study demonstrates the protective efficacy of a new Leishmania protein against VL, when it is administered as a DNA vaccine or a recombinant protein plus saponin, and points out its use as a human vaccine against disease.
ISSN: 00088749
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_EvaluationLeishmaniaHypothetical.pdf1,99 MBAdobe PDFView/Open    Request a copy

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.